All of the active B12 group reporting anti showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented inflammatory by Dr. O''Connor to the FDA. The FDA panel acknowledged anti the safety of the treatment. The panel seemed to be in agreement that the statistics indicated inflammatory a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, anti Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

With no further treatment, the 1996 ten-month follow-up inflammatory data (n=92) from a high pollen period in Oregon, anti Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary inflammatory endpoint, defined as a combination of symptom and rescue medication anti scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels inflammatory to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

©2003 www.asian-homeopathic-remedies.com All rights reserved.